Press releaseGlobe Newswire
NewAmsterdam Pharma Company NV
NAMSW · NASDAQ
$9.25−$1.75 (−15.91%)TodayMarket closed ·
Prev close $11.00
Latest news
- Press releaseGlobe Newswire
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
- Press releaseGlobe Newswire
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
- Press releaseGlobe Newswire
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
- Press releaseGlobe Newswire
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
- Press releaseGlobe Newswire
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
- Press releaseGlobe Newswire
NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
- Press releaseGlobe Newswire
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
- Press releaseGlobe Newswire
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.